Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 00773J202 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Fairmount Funds Management LLC
13D/A
Amendment 8
|
10.0% |
10/9/2026
Event 10/7/2026
|
|
| Fairmount Funds Management LLC | 9.2% | ||
| Fairmount Healthcare Fund II L.P. | 9.2% | ||
| Harwin Peter Evan | 10.0% | ||
| Kiselak Tomas | 10.0% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.1% |
10/1/2026
Event 9/24/2026
|
|
| Paradigm BioCapital Advisors LP | 5.1% | ||
| Paradigm BioCapital Advisors GP LLC | 5.1% | ||
| Senai Asefaw, M.D. | 5.1% | ||
| Paradigm BioCapital International Fund Ltd. | 4.5% | ||
|
RTW Investments, LP
13G/A
Amendment 2
|
4.8% |
8/14/2026
Event 6/30/2026
|
|
| RTW Investments, LP | 4.8% | ||
| Roderick Wong | 4.8% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 1
|
4.9% |
8/14/2026
Event 6/30/2026
|
|
| Perceptive Advisors LLC | 4.9% | ||
| Joseph Edelman | 4.9% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 4.9% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 7
|
10.0% |
6/23/2026
Event 6/23/2026
|
|
| Fairmount Funds Management LLC | 9.2% | ||
| Fairmount Healthcare Fund II L.P. | 9.2% | ||
| Peter Evan Harwin | 10.0% | ||
| Tomas Kiselak | 10.0% | ||
|
Perceptive Advisors LLC
13G
|
5.0% |
4/22/2026
Event 4/15/2026
|
|
| Perceptive Advisors LLC | 5.0% | ||
| Joseph Edelman | 5.0% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 5.0% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 6
|
10.0% |
4/20/2026
Event 4/16/2026
|
|
| Fairmount Funds Management LLC | 9.1% | ||
| Fairmount Healthcare Fund II L.P. | 9.1% | ||
| Peter Harwin | 10.0% | ||
| Tomas Kiselak | 10.0% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Tang Capital Management LLC
13G/A
Amendment 1
|
2.4% |
2/17/2026
Event 12/31/2025
|
|
| Tang Capital Management, LLC | 2.4% | ||
| Kevin Tang | 2.4% | ||
| Tang Capital Partners, LP | 1.3% | ||
| Tang Capital Partners International, LP | 1.1% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 5
|
10.0% |
10/17/2025
Event 10/15/2025
|
|
| Fairmount Funds Management LLC | 9.0% | ||
| Fairmount Healthcare Fund II L.P. | 9.0% | ||
| Peter Evan Harwin | 10.0% | ||
| Tomas Kiselak | 10.0% | ||
| Vanguard Group Inc 13G | 5.1% |
7/29/2025
Event 6/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 6.6% |
7/16/2025
Event 6/30/2025
|
|
|
Tang Capital Management LLC
13G
|
5.3% |
5/1/2025
Event 4/24/2025
|
|
| Tang Capital Management, LLC | 5.3% | ||
| Kevin Tang | 5.3% | ||
| Tang Capital Partners, LP | 3.0% | ||
| Tang Capital Partners International, LP | 2.3% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
4.6% |
2/14/2025
Event 12/31/2024
|
|
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | ||
| VHCP Co-Investment Holdings III, LLC | 4.6% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 4.6% | ||
| VHCP Management III, LLC | 4.6% | ||
| VHCP Management EG, LLC | 4.6% | ||
| Nimish Shah | 4.6% | ||
| Bong Y Koh | 4.6% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 3
|
4.4% |
2/14/2025
Event 12/31/2024
|
|
| Perceptive Advisors LLC | 4.4% | ||
| Joseph Edelman | 4.4% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 4.4% | ||
|
RTW Investments, LP
13G/A
Amendment 1
|
6.2% |
2/14/2025
Event 12/31/2024
|
|
| RTW Investments, LP | 6.2% | ||
| Roderick Wong, M.D. | 6.2% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 1.94 k | $172 k |
| 2026 Q2 | 277 | 102 M | $8.58 B |
| 2026 Q1 | 205 | 82.8 M | $4.17 B |
| 2025 Q4 | 159 | 81.0 M | $2.60 B |
| 2025 Q3 | 143 | 64.6 M | $1.08 B |
| 2025 Q2 | 134 | 63.6 M | $953 M |
| 2025 Q1 | 136 | 62.1 M | $1.00 B |
| 2024 Q4 | 135 | 59.9 M | $1.39 B |
| 2024 Q3 | 124 | 51.4 M | $1.51 B |
| 2024 Q2 | 114 | 51.4 M | $1.21 B |
| 2024 Q1 | 106 | 31.7 M | $1.20 B |
| 2023 Q4 | 59 | 28.0 M | $601 M |
| 2023 Q3 | 30 | 3.26 M | $39.9 M |